Efficacy and safety of gabapentinoid combination therapy versus monotherapy for the treatment of neuropathic pain.

TL;DR

A meta-analysis of 21 clinical trials found that combining gabapentinoids (gabapentin or pregabalin) with other medications or supplements produces greater reductions in neuropathic pain compared to gabapentinoid monotherapy . However, safety profiles vary significantly by combination type, with opioid-gabapentinoid pairings carrying notably higher discontinuation and adverse event rates.

What the Study Found

Researchers conducted a systematic review and meta-analysis of 21 head-to-head comparative trials involving 2,204 patients to evaluate whether combining gabapentinoids with other agents outperforms single-agent gabapentinoid treatment for neuropathic pain. The analysis examined multiple pain conditions including diabetic neuropathy, postherpetic neuralgia, and other neuropathic syndromes, with outcomes spanning pain severity, sleep quality, patient-reported improvement, and safety signals.

Combination therapy demonstrated measurable superiority across the primary outcomes. Patients receiving gabapentinoid combination therapy experienced greater pain reduction on a 0-10 scale compared to monotherapy (mean difference of 1.27 points), which represents a clinically meaningful reduction. Sleep interference scores also improved more significantly with combinations (mean difference of 0.92 points). When examining patient global impression of change, those on combination therapy were 1.8 times more likely to report meaningful improvement compared to monotherapy groups. These findings held across 18 pain reduction studies, 5 sleep studies, and 4 response rate studies respectively.

The benefit of combination therapy was not uniform across all add-on agents. Gabapentinoids combined with antidepressants, dietary supplements, local anesthetics, non-pharmacological interventions, and other gabapentinoids all showed statistically significant pain reductions. Opioid-gabapentinoid combinations and combinations with immunomodulators showed less clear benefit patterns. Notably, patients with specific neuropathic pain diagnoses appeared to benefit more from combination approaches: those with painful diabetic neuropathy and postherpetic neuralgia demonstrated greater absolute gains with combined therapy compared to other neuropathic pain types.

The safety analysis revealed an important trade-off. Overall discontinuation rates were higher with combination therapy than monotherapy, driven substantially by opioid-gabapentinoid combinations, which carried elevated risks for adverse events. However, most non-opioid combinations maintained safety profiles comparable to gabapentinoid monotherapy alone. This distinction is clinically relevant: the safety signal was not inherent to combination therapy broadly, but rather specific to opioid pairings. The authors noted that adverse event patterns differed by combination type, suggesting that careful selection of co-agents matters considerably for the benefit-risk calculation.

What This Means for You

If you have neuropathic pain currently managed with gabapentin or pregabalin monotherapy, these findings suggest discussing combination approaches with your clinician, particularly if pain control remains suboptimal. The evidence points toward genuine incremental benefit, not marginal improvement.

The practical translation depends on your specific condition and current regimen. Combination therapy with antidepressants or supplements may offer better pain control with acceptable safety compared to increasing gabapentinoid dose alone. If opioids are being considered as an add-on, this analysis highlights particular caution: while combinations exist in clinical practice, the safety profile appears less favorable, and alternative combination strategies may warrant consideration first.

For conditions like painful diabetic neuropathy or postherpetic neuralgia specifically, the evidence base for combination therapy appears stronger than for other neuropathic pain types. If you have one of these diagnoses, combination therapy may deserve earlier discussion rather than dose escalation of monotherapy.

This research does not establish which specific non-opioid combinations work best for individual patients, so clinical judgment and individualized trial-and-error remain necessary. The meta-analysis confirms the category benefit but cannot eliminate the need to find your optimal combination through guided clinical experimentation.

Study Details

Sources